Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tauns Laboratories, Inc. ( (JP:197A) ) has issued an update.
TAUNS Laboratories, Inc. has announced a Master Transaction Agreement with Roche Diagnostics K.K., under which TAUNS will supply Roche with two diagnostic products: ImunoAce SARS-CoV-2 III and ImunoAce SARS-CoV-2/Flu. The sales are set to begin in the last week of January 2025. While the immediate impact on TAUNS’s business performance is expected to be minimal, the company will provide updates if significant effects are identified.
More about Tauns Laboratories, Inc.
TAUNS Laboratories, Inc. operates in the healthcare industry, focusing on the development and sale of diagnostic products. The company is primarily involved in providing diagnostic solutions, with a market focus on innovative testing products.
YTD Price Performance: 1.45%
Average Trading Volume: 933,666
Technical Sentiment Consensus Rating: Strong Sell
For a thorough assessment of 197A stock, go to TipRanks’ Stock Analysis page.
